Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Meiragtx Holdings Plc (MGTX)

Meiragtx Holdings Plc (MGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 394,845
  • Shares Outstanding, K 64,307
  • Annual Sales, $ 14,020 K
  • Annual Income, $ -84,030 K
  • EBIT $ -169 M
  • EBITDA $ -154 M
  • 60-Month Beta 1.29
  • Price/Sales 27.50
  • Price/Cash Flow N/A
  • Price/Book 4.82

Options Overview Details

View History
  • Implied Volatility 49.16% ( -53.19%)
  • Historical Volatility 61.42%
  • IV Percentile 23%
  • IV Rank 8.91%
  • IV High 398.13% on 04/25/24
  • IV Low 15.04% on 08/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 153
  • Volume Avg (30-Day) 79
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 2,736
  • Open Int (30-Day) 2,440

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.47
  • Number of Estimates 1
  • High Estimate -0.47
  • Low Estimate -0.47
  • Prior Year -0.74
  • Growth Rate Est. (year over year) +36.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.94 +55.84%
on 09/24/24
6.22 -1.29%
on 10/18/24
+1.85 (+43.12%)
since 09/18/24
3-Month
3.85 +59.48%
on 09/03/24
6.22 -1.29%
on 10/18/24
+1.47 (+31.48%)
since 07/18/24
52-Week
3.49 +75.93%
on 10/25/23
7.60 -19.21%
on 12/26/23
+2.12 (+52.74%)
since 10/18/23

Most Recent Stories

More News
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

MGTX : 6.14 (+3.37%)
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

MGTX : 6.14 (+3.37%)
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

-- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)...

MGTX : 6.14 (+3.37%)
MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

- Credit facility is collateralized by MeiraGTx’s wholly-owned manufacturing facilities in London, UK and Shannon, Ireland - $75 million at closing...

MGTX : 6.14 (+3.37%)
MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to

• The primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated ...

MGTX : 6.14 (+3.37%)
MeiraGTx Reports First Quarter 2022 Financial and Operational Results

- Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing...

MGTX : 6.14 (+3.37%)
MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

LONDON and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage gene therapy...

MGTX : 6.14 (+3.37%)
MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

LONDON and NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene...

MGTX : 6.14 (+3.37%)
MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

- Phase 3 Lumeos Clinical Trial of botaretigene sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Enrolling and Dosing...

MGTX : 6.14 (+3.37%)
MeiraGTx Receives Clinical Development Milestone Payment from Janssen

-MeiraGTx Receives $30 Million Cash Milestone Payment -MeiraGTx, in Collaboration with Janssen Pharmaceuticals, Inc., is Now Dosing Patients in the...

MGTX : 6.14 (+3.37%)

Business Summary

MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR,...

See More

Key Turning Points

3rd Resistance Point 6.65
2nd Resistance Point 6.43
1st Resistance Point 6.29
Last Price 6.14
1st Support Level 5.93
2nd Support Level 5.71
3rd Support Level 5.57

See More

52-Week High 7.60
Last Price 6.14
Fibonacci 61.8% 6.03
Fibonacci 50% 5.55
Fibonacci 38.2% 5.06
52-Week Low 3.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar